Impaired 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2)-dependent cortisol inactivation can lead to electrolyte dysbalance, hypertension and cardiometabolic disease. Furthermore, placental 11b-HSD2 essentially protects the fetus from high maternal glucocorticoid levels, and its impaired function has been associated with altered fetal growth and a higher risk for cardio-metabolic diseases in later life. Despite its important role, 11b-HSD2 is not included in current off-target screening approaches. To identify potential 11b-HSD inhibitors among approved drugs, a pharmacophore model was used for virtual screening, followed by biological assessment of selected hits. This led to the identification of several azole fungicides as 11b-HSD inhibitors, showing a significant structure-activity relationship between azole scaffold size, 11b-HSD enzyme selectivity and inhibitory potency. A hydrophobic linker connecting the azole ring to the other, more polar end of the molecule was observed to be favorable for 11b-HSD2 inhibition and selectivity over 11b-HSD1. The most potent 11b-HSD2 inhibition, using cell lysates expressing recombinant human 11b-HSD2, was obtained for itraconazole (IC 50 139 ± 14 nM), its active metabolite hydroxyitraconazole (IC 50 223 ± 31 nM) and posaconazole (IC 50 460 ± 98 nM). Interestingly, experiments with mouse and rat kidney homogenates showed considerably lower inhibitory activity of these compounds towards 11b-HSD2, indicating important species-specific differences. Thus, 11b-HSD2 inhibition by these compounds is likely to be overlooked in preclinical rodent studies. Inhibition of placental 11b-HSD2 by these compounds, in addition to the known inhibition of cytochrome P450 enzymes and P-glycoprotein efflux transport, might contribute to elevated local cortisol levels, thereby affecting fetal programming.
Introduction
11b-Hydroxysteroid dehydrogenase 2 (11b-HSD2) converts potent 11b-hydroxyglucocorticoids (cortisol, corticosterone) into their inactive 11-keto forms (cortisone, 11-dehydrocorticosterone), thereby controlling tissue-specific activities of mineralocorticoid receptors (MR) and glucocorticoid receptors (GR) [1] . 11b-HSD2 is essentially involved in the regulation of electrolyte balance, vascular function, and angiogenesis, as well as in the fetal-placental barrier to inactivate cortisol and protect the fetus from high maternal glucocorticoid levels [2, 3] .
The consequences of impaired 11b-HSD2 function are manifested in patients with genetic loss-of-function mutations suffering from apparent mineralocorticoid excess (AME) [2, 4, 5] . In these patients the excessive cortisol-dependent MR activation in the kidney and colon results in hypokalemia, hypernatremia and water retention, leading to severe hypertension characterized by low renin, low aldosterone and increased plasma and urinary cortisol to cortisone ratios. 11b-HSD2 activity is essential since very early on in life, because birth weights of individuals homozygous/compound heterozygous for HSD11B2 mutations were found to be significantly lower than those of their unaffected siblings [6] . Milder acquired forms of AME can be caused by inhibition of 11b-HSD2, for instance upon consumption of considerable amounts of licorice, containing the potent 11b-HSD inhibitor glycyrrhetinic acid (GA) [7] .
The exposure to 11b-HSD2 inhibitors is especially critical during pregnancy. 11b-HSD2 builds a placental barrier by protecting the fetus from the 5-10 times higher maternal glucocorticoid levels in the course of a normal pregnancy [8] [9] [10] [11] . Nevertheless, this barrier is not entirely complete, as a minor proportion of maternal cortisol is able to cross the placenta [11] . Glucocorticoids are important mediators of fetal growth, development and organ maturation. Rising total plasma cortisol levels during pregnancy, peaking in the third trimester at threefold non-pregnant levels [12] , are in parallel with progressive maturation of fetal organs, most notably the stimulation of surfactant production by the lung. However, glucocorticoid administration, especially during late gestation, has been associated with reduced birth weight, elevated blood pressure, higher insulin, increased distractibility and attention deficit later in life [13] [14] [15] [16] [17] . The correlation between low birth weight, albeit in normal ranges, and subsequent diseases in adulthood was found to be largely independent of confounding life style factors such as smoking or obesity [15] . It has been hypothesized that a reduced placental 11b-HSD2 activity is responsible for the high glucocorticoid concentrations reaching the fetus and subsequent programming of disease susceptibility [18] . Importantly, low 11b-HSD2 expression was found to be associated with intrauterine growth restriction pregnancies in humans and in rodent models [19] [20] [21] [22] . Determination of osteocalcin concentration in human cord blood samples, which is a sensitive marker of glucocorticoid exposure in adult humans, revealed a direct correlation with placental 11b-HSD2 activity [23] .
Treatment of pregnant rats with dexamethasone, which cannot be inactivated by 11b-HSD2 [24] , led to lower birth weights and caused HPA axis hyperactivity, hypertension, hyperglycemia and increased anxiety behavior [20, 25] . Similarly, administration of the unselective 11b-HSD inhibitor carbenoxolone to pregnant rats resulted in reduced birth weight, and adult offspring showed enhanced HPA activity with increased glucocorticoid and CRH levels as well as elevated blood pressure [26, 27] . Evidence for the importance of placental 11b-HSD2 was contributed by studies with placentas from 11b-HSD2-deficient mice showing increased amino acid and reduced glucose transport as well as lower expression levels of genes important for angiogenesis [28] . Furthermore, maternal stress and malnutrition in rats were reported to be able to down regulate placental 11b-HSD2 and program for diseases in adult life [29] [30] [31] . Factors including sex steroids, nitric oxide, prostaglandins, proinflammatory cytokines, infections and environmental pollutants were shown to have the potential to reduce 11b-HSD2 activity in studies using placental cell lines [32, 33] .
Observational studies showed that pregnant Finnish women consuming large amounts of licorice (containing the unselective 11b-HSD inhibitor glycyrrhetinic acid) had shorter gestation times [34] and gave birth to children with behavioral disturbances and poorer cognitive functions coupled with increased HPA axis activity, in a dose-dependent manner [35, 36] . Compromised 11b-HSD2 function during pregnancy has also been implicated in preeclampsia, a major cause of maternal and perinatal mortality; however, the etiology is poorly understood [37, 38] .
Due to its important physiological role and the adverse effects observed upon its inhibition, 11b-HSD2 can be considered as an anti-target for drug development (with a few specific exceptions where these effects are wanted); however, it is not included in current off-target screening approaches. The present study addressed possible inhibitory effects of approved drugs towards 11b-HSD2 by performing a virtual screening (VS) of the DrugBank database using an 11b-HSD pharmacophore model. This was followed by a biological evaluation of selected hits, with a focus on the azole fungicides itraconazole and posaconazole. 
Materials and methods

Chemicals and reagents
Pharmacophore modeling and virtual screening
The 11b-HSD inhibitor pharmacophore model used for this study was previously reported and validated [39] . The model was initially based on three potent, structurally diverse 11b-HSD inhibitors [40] and refined with recent literature and novel screening data (model 4new in reference [39] , Fig. 1A ).
To discover potential 11b-HSD inhibitors among FDA-approved drugs and nutraceuticals, the DrugBank version 3.0 was downloaded as sd file (1543 approved drugs and 84 nutraceuticals) and transformed into a 3D-multiconformational database using the ''build database" protocol of Discovery Studio 4.0 (Discovery Studio, Version 4.0, Biovia Inc., San Diego, CA, 2014). For each compound, a maximum of 255 conformers was calculated using fast settings. For the VS, the ''search 3D database" protocol with BEST flexible search was used. The DrugBank database was screened with the 11b-HSD inhibitors model using Discovery Studio 4.0.
Cell culture
Human Embryonic Kidney-293 cells (HEK-293) cells (used at passage number [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , human SW-620 colon carcinoma cells (passage number [11] [12] [13] [14] [15] and human MCF-7 breast cancer cells (passage number [19] [20] [21] [22] [23] [24] [25] [26] [27] were obtained from ATCC (Manassas, VA, USA) and were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 4.5 g/L glucose, 100 U/mL penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES, pH 7.4, and 10% MEM non-essential amino acid solution.
Determination of 11b-HSD activity in cell lysates
Enzyme activities were determined as described earlier using lysates of HEK-293 cells stably expressing human 11b-HSD1 and hexose-6-phosphate dehydrogenase (H6PDH; HHH7 clone) or 11b-HSD2 (AT8 clone) [41] . 11b-HSD1 reductase activity was measured by incubating the lysates for 10 min at 37°C in a total volume of 22 lL containing 200 nM radiolabeled cortisone, 500 lM NADPH and test substance or vehicle (DMSO at a maximal concentration of 0.1%). 11b-HSD2-dependent oxidation was assessed in the presence of 200 nM radiolabeled cortisol and 500 lM NAD + . The reactions were stopped by adding an excess amount of unlabeled cortisone and cortisol (1:1, 2 mM in methanol). Approximately 20-25% of the substrate were converted to the corresponding product. Steroids were separated by thin layer chromatography (TLC) using chloroform and methanol (9:1). Conversion of radiolabeled substrate was measured by scintillation counting. The substrate conversion was determined and compared to the enzyme activity in the control sample.
To exclude irreversible 11b-HSD2 inhibition by the investigated compounds, HEK cell lysates were preincubated with the corresponding compounds for 0, 5 and 20 min at 4°C, followed by determination of enzyme activity. Alternatively, lysate were preincubated with the compounds for 10 min followed by subsequent dilution (1:2 or 1:4) and determination of enzyme activity [42] . Data (mean ± SD) were normalized to vehicle control (DMSO) and obtained from at least three independent experiments.
Determination of 11b-HSD2 activity in intact cells
11b-HSD2 activity measurement in intact SW-620 and MCF-7 cells was determined as described earlier [43] . Briefly, 100,000 SW-620 and 50,000 MCF-7 cells per well were seeded in 96-well plates. The medium was replaced after 24 h by 40 lL steroidand serum-free DMEM (DMEMsf) containing either vehicle or inhibitor and 10 lL medium containing 10 nCi radiolabeled cortisol and unlabeled cortisol to reach a final concentration of 50 nM. SW-620 cells were incubated for 4 h and MCF-7 cells for 5 h at 37°C, followed by analysis of steroid conversion by TLC and scintillation counting.
Determination of 17b-HSD1 and 17b-HSD2 activity in cell lysates
Determination of 17b-HSD1 and 17b-HSD2 activity was conducted as described earlier [44] . Briefly, lysates of HEK-293 cells transiently expressing human 17b-HSD1 and 17b-HSD2 were incubated for 10 min at 37°C in a total volume of 22 lL in the presence 200 nM estrone containing 50 nCi of [2, 4, 6, H]-estrone and 500 lM NAPDH for 17b-HSD1, and with 200 nM estradiol containing 50 nCi of [2, 4, 6, H]-estradiol and 500 lM NAD + for 17b-HSD2 activity measurements. Steroids were separated using TLC and substrate conversion determined by scintillation counting. Data (mean ± SD) were normalized to vehicle control (DMSO) and obtained from at least three independent experiments.
Determination of 11b-HSD activity in mouse and rat kidney homogenates
Mouse (C57BL6) and rat (Wistar) kidney tissue from adult males were snap frozen in liquid nitrogen and stored at À80°C until further use. For homogenate preparation, frozen tissue was sonicated in homogenization buffer (250 mM sucrose, 10 mM HEPES, pH 7.4; 900 lL for 100 mg of kidney) and centrifuged at 2000g, 4°C for 10 min to remove cell debris. The total protein concentration was determined by BCA assay [45] . The homogenates were prediluted to a protein concentration of 3.75 mg of protein/ mL (mouse) or 10 mg of protein/mL (rat) in homogenization buffer.
Reactions were performed in a total volume of 22 lL incubation buffer (300 mM NaCl, 20 mM Tris(hydroxymethyl)aminome thane-hydrochloride, 1 mM EDTA, 10% glycerol, pH 7.7) containing 0.075 mg/mL of mouse and 0.2 mg/mL of rat total kidney protein, respectively, as well as 10 lM of test compound, 50 nM of corticosterone (containing 50 nCi [1,2,6,7- were converted. The steroids were separated by TLC and conversion of radiolabeled substrate was measured by scintillation counting.
Docking
Docking was performed using GOLD 5.2 (The Cambridge Crystallographic Data Centre, Cambridge, UK, [46] ) based on a crystal structure of 11b-HSD1 (co-crystallized with (2R)-4-[4-fluoro-2-(tri fluoromethyl)phenyl]-2-methyl-1-([3-(1H-1,2,4-triazol-1-yl)ph enyl]sulfonyl)piperazine, PDB code 3HFG [47] ) and a homology model for human 11b-HSD2 [48] and murine 11b-HSD2 [49] . The PDB entry 3HFG was chosen for two reasons. First, it was the template for generating the homology model of human and murine 11b-HSD2. Second, the co-crystallized inhibitor is of similar size as some of the investigated antifungals and contains a triazole moiety. It therefore probably constitutes a binding site conformation suitable for docking this class of 11b-HSD1 inhibitors. The ligand binding pocket was defined as a sphere with a 10 Å radius around the coordinates X = À19.50 Y = 4.00, Z = 14.25. ChemPLP was used as scoring function. As workflow validation, redocking of the original ligand was performed using default settings and the best ranked pose deviates from the crystal structure with an RMSD of 0.856 for 11b-HSD1. As both the homology models for human and murine 11b-HSD2 were initially based on PDB entry 3HFG, the same coordinates were used to define the binding site for this docking. For human 11b-HSD2, the docking was additionally repeated setting Arg212 as flexible amino acid. The binding poses were analyzed using LigandScout 4.1 [50] (Inte:Ligand GmbH, Vienna, Austria).
Results
Virtual screening of the DrugBank database using a 11b-HSD pharmacophore model and virtual hit selection for biological evaluation
Despite its role in the regulation of electrolyte balance and cardiovascular function and its importance during pregnancy to control the in utero environment and therefore fetal growth and development, 11b-HSD2 is not included in current drug off-target screenings. Thus, the present project aimed to evaluate some approved drugs for their ability to interfere with 11b-HSD2 activity. For this purpose, the FDA-approved small molecule drug entries of the DrugBank database were subjected to VS using a previously developed 11b-HSD pharmacophore model (Fig. 1A) [39] . This model is not expected to discriminate between 11b-HSD1 and 11b-HSD2 inhibitors because no crystal structure is available for 11b-HSD2 and the model is, at least in part, built based on available 11b-HSD1 ligands. Of the 1543 DrugBank entries, 101 approved drugs fitted into the model. Not surprisingly, several steroidal compounds (in total 18 hits) including mainly glucocorticoids, were among the hits. Besides, the virtual hit list contained several prostaglandin analogues as well as anti-infective agents, including antifungals, antibiotics and antiparasitic agents. Antifungals were especially represented by the class of azole fungicides, with sertaconazole, butoconazole and tioconazole as virtual hits (Fig. 1B) . The majority of antibiotics comprised b-lactam antibiotics and lincosamides, with cloxacillin, flucloxacillin and nafcillin, as well as clindamycin and lincomycin as representative structural classes. Further virtual hits included members of the classes of anti hypertensives/antiarrhythmics, diuretics, lipid lowering drugs, antidiabetics, analgesics and antipsychotics. Several hits from the VS, belonging to the different structural classes mentioned above and available through an in-house chemical repository, were selected for biological assessment.
Effect of selected virtual hits and further structurally related compounds on 11b-HSD activity
The selected compounds were first tested for their potential to inhibit cortisol to cortisone conversion in lysates of HEK-293 cells stably expressing human 11b-HSD2. The selectivity over the closely related 11b-HSD1 was then determined by measuring the effect of the chemicals on the conversion of cortisone to cortisol. The selected steroids (nandrolone), antiarrhythmics (amiodarone), lipid lowering drugs (atorvastatin, simvastatin), diabetics (rosiglitazone), diuretics (ethacrynic acid), analgesics (indomethacin, nabilone), antipsychotics/sedative (chlorpromazine), the uricosuric probenecid, antiparasitic agents (amodiaquine, chloroquine and pentamidine), b-lactam antibiotics (cloxacillin, flucloxacillin and nafcillin), lincosamides (clindamycin and lincomycin) and the steroid-like antibiotic fusidic acid showed no or weak inhibition (less than 40% inhibition) of 11b-HSD1 and 11b-HSD2 enzyme activity at a concentration of 20 lM (data not shown). However, the azole fungicides sertaconazole, butoconazole and tioconazole showed moderate activity and inhibited 11b-HSD2 at a concentration of 20 lM, resulting in 61%, 44% and 50% residual activity, respectively. These azole fungicides were not selective, and they equally well or preferentially inhibited 11b-HSD1, showing residual enzyme activities of 35%, 48% and 18%, respectively.
Due to their wide use and partial over-the-counter availability, and their previous association with 11b-HSDs (triadimefon as a substrate of 11b-HSD1 and ketoconazole as a weak inhibitor of 11b-HSD1 and 11b-HSD2 [39, 51] ), additional, structurally related azole fungicides were selected for biological testing in order to provide proof of concept in applying pharmacophores as initial filter for the identification of hazardous compound classes [52] . The biological analyses using HEK-293 cell lysates expressing recombinant human enzymes revealed a clear structure-activity relationship between 11b-HSD selectivity and structural size and shape of the azoles: the larger the structural size the more potent its inhibitory activity against 11b-HSD2 and the higher the selectivity over 11b-HSD1 (Fig. 2) . One requirement of high activity was a hydrophobic central region of the azole scaffold linked to a more polar end. The compounds with a smaller scaffold preferentially inhibited 11b-HSD1. In addition, the subdivision of azoles in imidazole and triazole derivatives revealed a further relationship. Imidazoles such as tioconazole, sertaconazole and butoconazole preferably inhibited 11b-HSD1 over 11b-HSD2, whereas triazoles such as terconazole, posaconazole and itraconazole more potently inhibited 11b-HSD2. Albendazole, possessing a small azole scaffold containing a benzimidazole structure, was inactive against both enzymes. The most potent 11b-HSD2 inhibition was found for itraconazole and posaconazole, with IC 50 values of 139 ± 14 nM and 460 ± 98 nM (Fig. 3) , respectively, and selectivity over 11b-HSD1 (Fig. 2) . Furthermore, as itraconazole is mainly metabolized to the pharmacologically active OHI, this metabolite was also tested, yielding an IC 50 value of 223 ± 31 nM against 11b-HSD2. Irreversible 11b-HSD2 inhibition by itraconazole, OHI and posaconazole was excluded by preincubation experiments; however, preincubation did not alter the inhibitory effect, suggesting a competitive mode of inhibition in line with competition for substrate binding.
Selectivity assessment of the azole fungicides over 17b-HSD1 and 17b-HSD2
Although 11b-HSD2 and 11b-HSD1 are responsible for the interconversion of the same substrate, i.e. glucocorticoids, they are distant homologs sharing only about 18% sequence identity [53] . In contrast, human 17b-HSD2 is more closely related to 11b-HSD2 with about 45% amino acid sequence identity. 17b-HSD2 is predominantly involved in the metabolism of sex steroid hormones, inactivating estradiol to estrone, testosterone into D4-androstene-3,17-dione (androstenedione), 5a-dihydrotestosterone (DHT) into 5a-androstanedione or 5-androstene-3b,17b-diol to dehydroepiandrosterone (DHEA). The reverse reaction of activating the weak estrogen estrone to the potent estradiol and to a minor extent DHEA to 5-andros tene-3b,17b-diol is catalyzed by 17b-HSD1. Due to the high expression of 17b-HSD1 and 17b-HSD2 in placenta [54, 55] , itraconazole, OHI and posaconazole were assessed for their potential to inhibit 17b-HSD1 and 17b-HSD2 enzyme activity in lysates of HEK-293 cells transiently expressing human 17b-HSD1 and 17b-HSD2. None of the compounds inhibited 17b-HSD1 or 17b-HSD2 activity (data not shown).
Species-specific 11b-HSD2 inhibition by the selected azole fungicides
Earlier studies emphasized the importance to assess speciesspecific differences of 11b-HSD1 and 11b-HSD2 inhibitors, espe-cially prior to conducting in vivo experiments [43, 51, 56] . Thus, prior to designing a rodent study to assess the effect of the selected azole fungicides on glucocorticoid inactivation, inhibition of 11b-HSD2 by itraconazole, OHI and posaconazole was further analyzed in rat and mouse kidney homogenates incubated with 50 nM of the rodent substrate corticosterone in the absence or presence of 10 lM test compound. In a qualitative comparison to the potent activity against recombinant human 11b-HSD2, which was expressed in HEK-293 cells and measured upon incubation with 200 nM of the human substrate cortisol, considerably lower inhibitory activity was detected against the rat and mouse enzymes. The different concentrations of corticosterone and cortisol used for rodent and human 11b-HSD2, respectively, reflect the approximately 5-10-fold affinity difference for these substrates [57, 58] . Itraconazole (Fig. 4A) and OHI (Fig. 4B) were at least 10-fold less potent towards rat and mouse 11b-HSD2 compared to the human enzyme, while posaconazole (Fig. 4C ) tended to be 2 times less active against rat 11b-HSD2 and was about 4 times less active against mouse 11b-HSD2. Although the activities of the human and rodent enzymes were measured under different conditions, considering their different physiological substrates, the data suggest a higher inhibitory activity of these azole fungicides towards human 11b-HSD2 compared to the rodent enzymes.
Inhibition of 11b-HSD2 in cell models with endogenous enzyme expression
To determine the inhibitory potential of itraconazole, OHI and posaconazole in intact cell systems, SW-620 and MCF-7 cells expressing relatively high endogenous 11b-HSD2 levels [43] 
Predicted binding of selected fungicides to 11b-HSD1 and 11b-HSD2
Docking studies with 11b-HSD1 showed two important proteinligand interactions for azole fungicides such as sertaconazole and tioconazole: a hydrophobic contact with Tyr183 and a hydrogen bond of the azole ring with the backbone nitrogen of Ala172 (Fig. 5A ). This hydrogen bond interaction was also the only ligand-coordinating hydrogen bond observed in the 11b-HSD1 crystal structure co-crystallized with a sulfonyl-piperazine inhibitor and thus, presumably essential for the inhibitory activity. In contrast, terconazole does not form any hydrogen bonds with the binding pocket of 11b-HSD1. Furthermore, docking of itraconazole and posaconazole revealed steric clashes with Thr124, Thr222 and Ala226 of the 11b-HSD1 substrate binding pocket, providing an explanation for their inactivity towards 11b-HSD1. However, a major difference between 11b-HSD1 and 11b-HSD2 is the shape of the binding site entry. While Met233 flanks the binding site entry of 11b-HSD1, Arg212 replaces this amino acid at the analogous position in 11b-HSD2. The difference in size and electrostatic properties of these amino acids likely influences the inhibitory activity. Indeed, all 11b-HSD2 active compounds analyzed formed an interaction with Arg212. Furthermore, the extended azole scaffolds were found to form additional interactions in their docking poses with 11b-HSD2, pointing towards tighter binding to the protein. Interestingly, itraconazole and posaconazole did not fit entirely into the binding site of 11b-HSD2 but rather lined the surface next to the binding site entry with their azole part (Fig. 5B) . Moreover, the additional hydroxyl group of posaconazole was able to form several hydrogen bonds with the phosphate moiety of NADPH.
To rationalize the relative selectivity of the three azole compounds to inhibit human 11b-HSD2, they were also docked into the murine homology model [49] . The murine 11b-HSD2 homology model revealed some crucial differences in the amino acid sequence compared to the human 11b-HSD2. Unlike the equivalent Arg212 on human 11b-HSD2, Arg279 on mouse 11b-HSD2 was not flanking the binding pocket entrance but oriented away (Fig. 5C) . Furthermore, part of the binding cavity near the cofactor was occupied by Trp276, a residue located outside the binding pocket in human 11b-HSD2, and this residue caused itraconazole to adopt a different angle within the binding cavity in the docking simulation. Additionally, the docking poses for itraconazole predicted no hydrogen bonds with the protein (Fig. 5D ). This missing structural anchoring provides an explanation for the weak activity of this fungicide towards murine 11b-HSD2. Interestingly, regarding murine 11b-HSD2, posaconazole and OHI showed greater inhibitory activity than itraconazole. Compared to itraconazole these two fungicides formed interactions with the cofactor via their hydroxyl groups (Fig. 5E) .
One important aspect of in silico-driven screening studies is the analysis of the predictions and a possible refinement of the model that was used for screening. The screening model performance was very powerful, as all three azole fungicides identified by the model (tioconazole, sertaconazole and butoconazole) inhibited 11b-HSD1 enzyme activity at a concentration of 20 lM by at least 50%. However, although itraconazole and posaconazole were represented in the DrugBank, they were not found by the model as virtual hits. A previous refinement study on this model [39] , addressed the shape restriction as one major restrictivity aspect. Shape deletion and subsequent VS of all tested compounds, including OHI, with this model retrieved all compounds except for climbazole as hits. For more thorough VS for potential 11b-HSD inhibitors, the shapeless model version may therefore be more suitable.
Discussion
Molecular modeling-based in silico approaches are important in drug development for the identification of bioactive molecules. Pharmacophore-based VS is a powerful strategy to enrich poten- tially active compounds among a large number of test compounds, thereby facilitating the identification of drug lead structures [59] . Such in silico tools are also applied in anti-target screenings; however, in contrast to lead compound identification this is more challenging since this approach aims to identify all potentially harmful substances. The present study applied a pharmacophore model based on 11b-HSD1 crystal structures for VS of the DrugBank database to find approved drugs that might inhibit 11b-HSD2, an enzyme not included in current off-target screenings during drug development. The goal was to identify, as a first step, structural compound classes inhibiting 11b-HSD2, followed by a more detailed analysis of a selected compound class including an in vitro validation of selected virtual hits.
The pharmacophore model used in this study demonstrated already earlier high predictive power [60] , and azole fungicides have been previously associated with 11b-HSDs: The azole fungicide triadimefon was reported to be a substrate of 11b-HSD1 (K m 3.5 lM), thereby acting as a weak competitive inhibitor (IC 50 15 lM) [51] . Ketoconazole was found to have weak inhibitory effects towards 11b-HSD1 and 11b-HSD2 [39, 61] . Thus, this compound class was chosen for further investigations. Biological evaluation revealed several azole fungicides as 11b-HSD inhibitors, showing a significant structure-activity relationship between azole scaffold size and 11b-HSD enzyme selectivity and potency of inhibition. The large scaffolds of itraconazole and posaconazole, which were not initial VS hits, potently inhibited 11b-HSD2 enzyme activity. Compared to terconazole, which was considerably less active on 11b-HSD2, itraconazole and posaconazole contain an extended hydrophobic central region and an additional triazolone side chain, which may form additional stabilizing interactions with the binding pocket, including Arg212, thereby providing an explanation for the potent inhibition. Thus, the VS approach has proven useful to identify azole fungicides as 11b-HSD2 inhibitors and to prioritize this compound class for further biological analyses, which were necessary to identify the most potent compounds itraconazole and posaconazole.
Itraconazole and posaconazole are clinically used for the prophylaxis and treatment of systemic mycotic infections and exert their mode of action by inhibiting the biosynthesis of ergosterol, an essential component of the fungal cell membrane [62, 63] . They can be applied for a prolonged period of time, up to years when used as prophylactic treatment, especially in immunosuppressed patients [64] . After oral exposure, itraconazole is extensively metabolized in the liver by cytochrome P450 3A4 (CYP3A4) to its main metabolite OHI, which retains potent 11b-HSD2 inhibitory activity. Thus, cortisol-dependent MR and GR activation due to prolonged 11b-HSD2 inhibition may contribute to the observed adverse effects of these fungicides. In contrast to itraconazole, hepatic metabolism of posaconazole plays a minor role and mainly involves conjugation by UDP-glucuronyltransferase UGT1A4 [65] . Although posaconazole is not a substrate of CYP3A4, it acts like itraconazole and OHI as a potent CYP3A4 inhibitor and it is therefore prone to considerable pharmacokinetic interactions with CYP3A4 substrates, including glucocorticoids [66, 67] . Inhibition of CYP3A4 by a single dose of itraconazole was shown to significantly decrease the formation clearance (CL f ) of the metabolites 6b-hydroxycortisol and 6b-hydroxycortisone [68] . Plasma cortisol and cortisone concentrations were not altered, indicating negative feedback regulation by the HPA axis and suggesting that cortisol levels are locally increased in CYP3A4 expressing tissues, particularly in the liver. Itraconazole, OHI and posaconazole might further promote local glucocorticoid effects by inhibiting P-glycoprotein (P-gp) mediated cortisol efflux [69, 70] . Besides its important role in the liver, P-gp expression has been detected in the human placenta from the first trimester to full-term [71] and P-gp was shown in vitro to support the placental 11b-HSD2 glucocorticoid barrier [72] .
Inhibition of 11b-HSD2 by itraconazole and posaconazole might impair glucocorticoid inactivation in the kidney, colon, vasculature and placenta. Indeed, Denolle et al. reported a case study of a patient on long-term itraconazole treatment developing hypokalemia, edema, hypertension, low plasma renin and aldosterone concentrations and normal serum cortisol, typical symptoms of AME as a result of cortisol-dependent MR activation [73] . Similar side effects including hypokalemia, edema, hypertension and mildly reduced aldosterone serum levels were described by Sharkey et al. for several patients during long-term itraconazole use [74] . Importantly, the drug safety sheet of Sporanox Ò (itraconazole)
reports hypokalemia and edema as occasionally (P1/1000, <1/100 patients) occurring, whereas the safety sheet for the i.v. solution of Noxafil Ò (posaconazole) notes hypokalemia as one of the most likely occurring adverse effect (22% of the reports) and a rise in blood pressure as frequent (1/100, <1/10) [75, 76] . Due to the high plasma protein binding capacity of itraconazole (99.8%), OHI (99.6%) and posaconazole (P98%), predominately to albumin, the circulating fraction of unbound drug is low [75, 76] . However, in specific situations the plasma protein binding capacity can be reduced. Pregnancy leads to several metabolic and physio- Itraconazole was found to exceed plasma concentrations in fat tissue approximately 17-fold and in lung, liver, muscle and kidney about 2-3-fold [64] . Less data are available for posaconazole, although it was shown that posaconazole concentrations are 31-42-fold higher in pulmonary alveolar cells compared with plasma [78] . Thus, the concentration of these triazole fungicides might also be elevated in placental tissue compared with plasma and therefore may reach relevant concentrations to inhibit 11b-HSD2 enzyme activity. Animal studies revealed embryotoxicity and teratogenicity with craniofacial and skeletal anomalies at concentrations exceeding those obtained at the maximum recommended human dose by 5-20-fold during itraconazole treatment but at concentrations lower than those observed at therapeutic doses during posacona- zole treatment [75, 76] . Therefore, it is recommended to use these drugs in pregnancy only if the benefit outweighs the potential risk. Extrapolation of findings from animal studies to human is often difficult due to species-specific differences. The present study provides evidence for a considerably weaker inhibition of mouse and rat 11b-HSD2 by itraconazole and OHI, and lower activity of posaconazole towards the rodent enzymes. Thus, 11b-HSD2-related effects on electrolyte balance, cardiovascular system and placental barrier function would be detected in rodent models only at much higher concentrations than in humans. Furthermore, regarding the latter, animal studies might be unreliable due to the highly variable 11b-HSD2 expression levels during gestation between different species. Mouse placental 11b-HSD2 mRNA drops towards late gestation, while rat placental 11b-HSD2 reduction occurs later and less pronounced. In contrast, human placental 11b-HSD2 levels are rising during gestation (reviewed by [13] ).
In a prospective cohort study, de Santis et al. evaluated first trimester exposure to itraconazole in 206 pregnant women compared with 207 unexposed controls [79] . The mean duration of the therapy was 6.9 ± 6.4 days with a daily dose of 182 ± 63 mg. No statistical difference between the exposed and the control group was found in terms of major congenital anomalies, premature birth or birth weight, but rates of live births and spontaneous abortion were higher in the exposed group. Bar-Oz et al. reported in a retrospective cohort study four times higher congenital malformation rates after first trimester exposure to itraconazole; however, strongly suggesting reporting bias due to retrospective data analysis [80] . The same authors found no difference in the rate of malformations compared to the control in a prospective cohort study with 229 women exposed to 50-800 mg itraconazole daily throughout 8.5 ± 12.4 days during the first trimester of pregnancy [81] . However, the rate live birth and the mean birth weight were lower in the exposed group compared to the control. No human data for prenatal posaconazole exposure have been published so far.
Developmental programming implies that an environmental factor affects fetal development during a sensitive time window to predispose the fetus towards diseases permanently throughout life [15] . A critical parameter includes the duration of the exposure to an environmental factor. The mean prenatal itraconazole exposure reported by de Santis et al. and Bar-Oz et al. was 6.9-8.5 days, thus shorter than the 15 days of treatment needed to reach plasma steady-state levels of itraconazole. This is important regarding 11b-HSD2 inhibition and thus prenatal programming through glucocorticoids. Several investigations found a reduction in birth weight in infants exposed to multiple courses of antenatal glucocorticoid therapy when adjusting for gestational age [82] [83] [84] . In addition, only first trimester itraconazole exposures were examined in the above described studies, but the effects of dexamethasone exposure on birth weight in rats was reported to be more pronounced when administered during later stages of pregnancy [85] . Chronic glucocorticoid treatment in mice was observed to impair the development of the cerebellum through inhibition of Sonic hedgehog (Shh) induced proliferation, a pathway important during embryonic growth and postembryonic tissue homeostasis. By upregulation of 11b-HSD2 expression Shh signaling partly antagonized the glucocorticoid-dependent effects, thus representing a feedback mechanism [86] . Interestingly, itraconazole, OHI and posaconazole were found to inhibit Shh signaling [87] [88] [89] , which may result in downregulation of 11b-HSD2 expression, thereby adding to the direct inhibitory effect of these azole fungicides.
Elevated glucocorticoid levels are known to inhibit angiogenesis, a crucial process during placental development that was shown to be inhibited by itraconazole [88, 90, 91] . Insufficient placental vascularization has been associated with intrauterine growth restriction, preeclampsia and fetal death, both in human and animal studies (reviewed by [92] ).
In conclusion, itraconazole, OHI and posaconazole were identified as novel potent inhibitors of human 11b-HSD2 by VS of the DrugBank database using an 11b-HSD pharmacophore model. Inhibition of placental 11b-HSD2 by these azole fungicides might contribute to an elevated local increase in cortisol levels, in addition to the known inhibition of cytochrome P450 enzymes and P-gp, thereby affecting fetal programming. Due to the observed species-specific differences, the consequences of placental 11b-HSD2 inhibition may have been overlooked in preclinical studies using rodents, although similar biological responses might be detected in rodents, albeit at higher concentrations.
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